Back to top
more

Galmed Pharmaceuticals (GLMD)

(Delayed Data from NSDQ)

$0.38 USD

0.38
91,134

-0.04 (-10.24%)

Updated Apr 15, 2024 03:59 PM ET

After-Market: $0.38 0.00 (1.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (153 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GLMD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Galmed Pharmaceuticals Ltd. [GLMD]

Reports for Purchase

Showing records 1 - 20 ( 192 total )

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 1

03/27/2023

Company Report

Pages: 4

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 2

01/06/2023

Daily Note

Pages: 3

Latest ARMOR Open Label Data Show Aramchol''s Potential in NASH; Galmed''s Future Remains Uncertain; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 3

11/17/2022

Company Report

Pages: 6

3Q Recap; Galmed''s Future Remains Uncertain; Search For Strategic Alternatives Continues; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 4

08/08/2022

Company Report

Pages: 7

2Q Recap; Aramchol and Amilo-5MER Both in Holding Pattern; Search For Strategic Alternatives Continues; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 5

07/14/2022

Daily Note

Pages: 3

Healthcare Coverage Update - Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 6

05/18/2022

Company Report

Pages: 7

1Q Recap: In NASH Limbo, Galmed Restructures; Considers Other Anti-Fibrotic Indications Beyond NASH; Maintain Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 7

05/03/2022

Company Report

Pages: 8

4Q Recap; Phase 3 Portion of ARMOR Trial Delayed to 2H23;Downgrade to Neutral on Uncertainty and Lack of Catalysts

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 8

01/12/2022

Daily Note

Pages: 3

Galmed Kicks Off 2022 With New Aramchol Patents and Positive Amilo-5MER Phase 1 Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 9

12/01/2021

Company Report

Pages: 9

3Q Recap; Initial Open Label Data From ARMOR Encouraging, Given Its Small Sample Size; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 10

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for GLMD

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 11

08/20/2021

Daily Note

Pages: 4

Publication Offers Mechanistic Rationale of Amilo-5MER''s Development For Chronic Inflammatory Diseases

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 12

08/16/2021

Daily Note

Pages: 3

2Q21 Results; Active 12 Months Ahead; Full Phase 2 Acne Data Expected in October

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 13

08/06/2021

Company Report

Pages: 8

2Q21 Recap: ARMOR Open Label Readout on Target in 4Q21 Ahead of Registrational Phase 3 Portion

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 14

08/02/2021

Daily Note

Pages: 4

FDA Agrees with Plan to Use Aramchol Meglumine in Phase 3 ARMOR Study; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 15

05/14/2021

Company Report

Pages: 8

1Q21 Recap; Expecting Open Label Data in 4Q21 to Inform Treatment Duration in Pivotal ARMOR; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 16

05/03/2021

Daily Note

Pages: 3

IND Approval in China a Key Step in Establishing ARMOR as a Global, Pivotal NASH Study; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 17

03/19/2021

Company Report

Pages: 9

ARMOR Resets to Incorporate Aramchol Meglumine in Phase 3; Moderate PT to $25 on Adjusted Clinical Timeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 18

03/17/2021

Daily Note

Pages: 3

First-in-Human Phase 1 Trial of Amilo-5MER Underway as Galmed Eyes Development for IBD; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 19

11/18/2020

Company Report

Pages: 8

3Q20 Recap: ARMOR Enrollment Struggles; December Milestones for Aramchol Meglumine and Amilo-5MER

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: Galmed Pharmaceuticals Ltd.

Industry: Medical - Drugs

Record: 20

11/10/2020

Daily Note

Pages: 3

Galmed Explores Potential of Bespoke Microbiome Treatment in Combination With Aramchol; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party